QUOTE AND NEWS
FiercePharma  Jun 20  Comment 
Novartis' Sandoz aims for 5 biosim launches by 2020 chelfand Mon, 06/20/2016 - 10:04
FierceBiotech  Jun 20  Comment 
UPDATED: Novartis, Novo-backed antifungal biotech F2G raises $60M badams Mon, 06/20/2016 - 06:46
FierceBiotech  Jun 16  Comment 
Pfizer, Novartis, BMS join $45M round for early fibrotic disease startup slawrence Thu, 06/16/2016 - 15:44
newratings.com  Jun 15  Comment 
Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment Novartis International AG / Novartis expands partnership with Medicines for Malaria Venture to develop next-generation...
Benzinga  Jun 13  Comment 
ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) received approval from the Food and Drug Administration of the Prior Approval Supplement for Oxcarbazepine Tablets, 150mg, 300mg and 600mg. According to the company, the current annual market for this...
newratings.com  Jun 10  Comment 
BASEL (dpa-AFX) - Novartis AG (NVS) Friday announced two positive study results involving Jakavi for polycythemia vera, a rare and incurable blood cancer, and Revolade in adults with chronic immune thrombocytopenia, a rare blood disorder. In a...
newratings.com  Jun 10  Comment 
Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV) Novartis International AG / Novartis presents data showing Jakavi® is superior to best available therapy in...
newratings.com  Jun 10  Comment 
Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder Novartis International AG / Novartis highlights long-term safety data of Revolade® in adults with chronic immune...
Motley Fool  Jun 9  Comment 
Investors are growing optimistic about upcoming phase 3 trial results for the company's lead drug candidate.
FierceBiotech  Jun 9  Comment 
Amgen, Novartis’ migraine drug hits endpoint in PhII trial ntaylor Thu, 06/09/2016 - 02:52




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki